12/10/2023 0 Comments Spark therapeuticsThe company also has SPK-8011, a gene therapy for Hemophilia A, in Phase III clinical studies, SPK-9001, a gene therapy for Hemophilia B it has partnered with Pfizer on in Phase III, and SPK-3006, in Phase I/II studies. 25, 2019 (GLOBE NEWSWIRE) Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that it has entered into a definitive merger agreement for Roche to fully acquire Spark Therapeutics at a price of 114.50 per. Spark Therapeutics spun out of Children’s Hospital of Philadelphia (CHOP) in 2013. On Chestnut Street, the building’s façade will have interactive color-changing lighting and LED display. The innovation center will include a “green roof” to promote stormwater management by collecting groundwater to use in the building’s rain garden, a modular design that leverages natural daylight, and a metal shading system to create heating efficiencies. Currently, Spark employs more than 800 people. These staff will be a combination of new hires and transfers from other Spark sites, continuing to strengthen Philly’s life science workforce. The Gene Therapy Innovation Center will house more than 500 staffers when it opens its doors in 2026. This sends the message to the rest of the world that Philadelphia is the place to be.” We want to do big things together, and today is a great example of that. Shapiro added, “Pennsylvania is open for business. Josh Shapiro said, “Philadelphia is going to be the gene therapy capital of the world.” Speaking at the groundbreaking ceremony, Pennsylvania Gov. The new space will provide more in-house manufacturing capacity and will become a ‘lighthouse’ facility for Spark and Roche, allowing cross-functional teams and partners to come together and work side by side to realize the full potential of gene therapy with unprecedented collaboration.” It is expected to offer increased in-house manufacturing capacity for Spark as well as for Roche and its subsidiary companies.Īlthough Spark declined to be interviewed for this article, the company supplied information and renderings of the facility, noting that it will “serve as Roche’s flagship center of excellence for gene therapy manufacturing globally. The center will be 500,000 square feet and six stories. The construction will more than double Spark’s physical footprint in the Philadelphia area. Originally announced in December 2021, Spark is investing $575 million in the innovation center located at the intersection of 30 th and Chestnut Streets. The FDA approved the drug in 2017 to treat patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. Spark, now a Roche company, developed the first FDA-approved gene therapy, Luxturna. Sixteen months since the original announcement, Spark Therapeutics broke ground this week on its Gene Therapy Innovation Center in University City on the Drexel University Campus in Philadelphia. (SOURCE: Spark Therapeutics) Spark Breaks Ground on Gene Therapy Innovation Center on Drexel Campus in Philadelphia, Paving the Way for Future Job Opportunities
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |